JAMA Oncology
Brief Report
April 25, 2024
Giacomo听Montagna,听MD, MPH; Mary M.听Mrdutt,听MD, MS; Susie X.听Sun,听MD; Callie听Hlavin,听MD, MPH; Emilia J.听Diego,听MD; Stephanie M.听Wong,听MD, MPH; Andrea V.听Barrio,听MD; Astrid Botty听van den Bruele,听MD; Neslihan听Cabioglu,听MD, PhD; Varadan听Sevilimedu,听MBBS, DrPH; Laura H.听Rosenberger,听MD, MS; E. Shelley听Hwang,听MD, MPH; Abigail听Ingham,听MBchB; B盲rbel听Papassotiropoulos,听MD; Bich Doan听Nguyen-Str盲uli,听MD; Christian听Kurzeder,听MD; Danilo D铆az听Aybar,听MD; Denise听Vorburger,听MD; Dieter Michael听Matlac,听MD; Edvin听Ostapenko,听MD; Fabian听Riedel,听MD; Florian听Fitzal,听MD; Francesco听Meani,听MD; Franziska听Fick,听MD; Jacqueline听Sagasser,听MD; J枚rg听Heil,听MD, PhD; Hasan听Karanl谋k,听MD; Konstantin J.听Dedes,听MD; Laszlo听Romics,听MD, PhD; Maggie听Banys-Paluchowski,听MD, PhD; Mahmut听Muslumanoglu,听MD; Maria Del Rosario Cueva听Perez,听MD; Marcelo Ch谩vez听D铆az,听MD; Martin听Heidinger,听MD; Mathias K.听Fehr,听MD; Mattea听Reinisch,听MD; Mustafa听Tukenmez,听MD; Nadia听Maggi,听MD; Nicola听Rocco,听MD, PhD; Nina听Ditsch,听MD, PhD; Oreste Davide听Gentilini,听MD; Regis R.听Paulinelli,听MD, PhD; Sebasti谩n Sol茅听Zarhi,听MD; Sherko听Kuemmel,听MD, PhD; Simona听Bruzas,听MD; Simona听di Lascio,听MD; Tamara K.听Parissenti,听MD; Tanya L.听Hoskin,听MS; Uwe听G眉th,听MD; Valentina听Ovalle,听MD; Christoph听Tausch,听MD; Henry M.听Kuerer,听MD, PhD; Abigail S.听Caudle,听MD; Jean-Francois听Boileau,听MD, MSc; Judy C.听Boughey,听MD; Thorsten听K眉hn,听MD, PhD; Monica听Morrow,听MD; Walter P.听Weber,听MD
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578
This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.
JAMA Surgery
Original Investigation
June 7, 2023
Sherko听Kuemmel,听MD, PhD; Joerg听Heil,听MD, PhD; Simona听Bruzas,听MD; Elisabeth听Breit,听PhD, BSc; Dorothea听Schindowski; Hakima听Harrach,听MD; Ouafaa听Chiari,听MD; Karin听Hellerhoff,听MD; Elena听Bensmann,听MD; Volker听Hanf,听MD, PhD; Sven-Thomas听Gra脽hoff,听MD; Petra听Deuschle,听MD; Kerstin听Belke,听MD; Silke听Polata,听MD; Stefan听Paepke,听MD; Mathias听Warm,听MD, PhD; Johannes听Meiler,听MD; Christian听Schindlbeck,听MD, PhD; Wencke听Ruhwedel,听MD; Ulrike听Beckmann,听MD; Ulrich听Groh,听MD; Peter听Dall,听MD, PhD; Jens-Uwe听Blohmer,听MD, PhD; Alexander听Traut,听MD; Mattea听Reinisch,听MD
free access
JAMA Surg. 2023; 158(8):807-815. 10.1001/jamasurg.2023.1772
This cohort study assesses 3-year clinical outcomes in patients with node-positive breast cancer who underwent targeted axillary dissection alone or in combination with axillary lymph node dissection.
JAMA Oncology
Original Investigation
May 19, 2022
Jens-Uwe听Blohmer,听MD, PhD; Theresa听Link,听MD; Mattea听Reinisch,听MD; Marianne听Just,听MD; Michael听Untch,听MD; Oliver听St枚tzer,听MD; Peter A.听Fasching,听MD; Andreas听Schneeweiss,听MD; Pauline听Wimberger,听MD, PhD; Sabine听Seiler,听MD; Jens听Huober,听MD; Marc听Thill,听MD, PhD; Christian听Jackisch,听MD, PhD; Kerstin听Rhiem,听MD; Christine听Solbach,听MD; Claus听Hanusch,听MD; Fenja听Seither,听MSc; Carsten听Denkert,听MD; Knut听Engels,听MD; Valentina听Nekljudova,听PhD; Sibylle听Loibl,听MD; GBG and AGO-B
free access
JAMA Oncol. 2022; 8(7):1010-1018. 10.1001/jamaoncol.2022.1059
This randomized clinical trial assesses whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy increases the pathological complete response rate and which schedule is more effective.
JAMA Oncology
Original Investigation
February 4, 2021
Mattea听Reinisch,听MD; Sabine听Seiler,听MD; Tanja听Hauzenberger,听MD; Axel听Kamischke,听MD, PhD; Sabine听Schmatloch,听MD; Hans-Joachim听Strittmatter,听MD, PhD; Dirk-Michael听Zahm,听MD; Christian听Thode,听MD; Jenny听Furlanetto,听MD; Dominika听Strik,听MD; Volker听M枚bus,听MD, PhD; Toralf听Reimer,听MD, PhD; Bruno Valentin听Sinn,听MD; Elmar听Stickeler,听MD, PhD; Frederik听Marm茅,听MD, PhD; Wolfgang听Janni,听MD, PhD; Marcus听Schmidt,听MD, PhD; Christian听Rudlowski,听MD, PhD; Michael听Untch,听MD, PhD; Valentina听Nekljudova,听PhD; Sibylle听Loibl,听MD, PhD
free access
JAMA Oncol. 2021; 7(4):565-572. 10.1001/jamaoncol.2020.7442
This randomized, multicenter clinical trial assesses changes in estradiol levels in male patients with hormone receptor鈥損ositive breast cancer after treatment with aromatase inhibitor plus gonadotropin-releasing hormone analogue, with gonadotropin-releasing hormone analogue plus tamoxifen, or with tamoxifen alone.